Generic Name and Formulations:
Plerixafor 20mg/mL; soln for SC inj; preservative-free.
Company:
Genzyme Corporation
 
Select therapeutic use: Miscellaneous hematological agents
Indications for MOZOBIL:
In combination with granulocyte colony stimulating factor (G-CSF): To mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.

Adult:
Start after 4 days' treatment with G-CSF. Give approximately 11hrs before starting apheresis. Repeat up to 4 consecutive days. Base dose on actual body weight. 0.24mg/kg SC; max 40mg/day. Renal impairment (CrCl≤50mL/min): 0.16mg/kg; max 27mg/day.

Children:
Not established.

Warnings/Precautions:
Not for use in leukemia. May cause mobilization of tumor cells. Monitor blood and platelet counts (esp. neutrophils). Monitor for splenic rupture (eg, left upper quadrant/scapular or shoulder pain). Monitor for signs/symptoms of hypersensitivity during and after administration for at least 30mins. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Interactions:
May be potentiated by drugs that reduce renal function or compete for active tubular secretion.

Pharmacological Class:
Hematopoietic stem cell mobilizer.

Adverse Reactions:
Diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness, vomiting; anaphylactic shock, hypersensitivity reactions (may be serious), tumor cell mobilization, increased circulating neutrophils, decreased platelet counts, enlarged spleen, vasovagal reaction may occur.

How Supplied:
Single-use vials (1.2mL)—1